

**RESPONSE TO QUESTIONS RECEIVED FROM THE SHAREHOLDERS
IN RELATION TO THE ANNUAL GENERAL MEETING FY2019**

The Board of Directors (“**Board**”) of OEL (Holdings) Limited (“**Company**” and together with its subsidiaries, “**Group**”) would like to provide the following information in response to questions raised by the Shareholders in relation to the Company’s Annual General Meeting for the financial year ended 31 December 2019:

Question 1:

With respect to Joint Venture Agreement with Shanghai Suntec, it was said that the premise at the Aljunied building will be used as a Manufacturing Plant and according to Ms Zhao Xin, they will start work in July 2020. Given the pandemic and the specialized nature of production of the HIFU-2001, where is the Company going to get the manufacturing capabilities as well as specialized manpower? Are there government support or grants that the Company can tap into?

Company’s Response:

As announced on 9 June 2020, the Company intends to form the JV Company in July 2020. The Company is currently finalising the details with Shanghai Suntec and finalising its own manpower and resource requirements for the JV Company.

One of the grants that the Company is considering applying for is the Enterprise Development Grant by Enterprise Singapore. The Company will provide more information to shareholders as and when there are further developments.

Question 2:

With respect to the acquisition of Shanghai Longjian Hospital Management Co., Ltd. (“Shanghai Longjian”), can the Company provide some numbers (such as machine numbers, target revenue/profit projections, timelines) so that shareholders can understand better the Company’s plan and to instill more confidence?

Company’s Response:

The Company is still in the preliminary stages of planning and will provide more information to shareholders, as and when there are further developments.

Question 3:

Given that the Company is working with experts from China and with the Chinese government, and that a lot of local investors are unable to access or independently review the credentials of the medical experts, can the Company provide pictures, links so that shareholders can clearer view and appreciation of the medical experts?

Company's Response:

The company is currently making some brochures and materials to help shareholders understand more on the medical experts from China. Once these are in place, the information will be posted on the company's website.

Question 4:

As far as we know, the HIFU technology and machines are NOT new, and there are many companies in the US developing and using them, does the Company have the proprietary and IP rights to the technology? Can the Company elaborate more on this issue?

Company's Response:

As announced by the Company on 24 June 2020, the Company is currently applying all the required licenses and approvals from the Health Sciences Authority and the National Environment Agency and will keep shareholders updated in due course.

Question 5:

Given the pandemic and Singapore lock-down, has the pre-school been operational? If so, at what capacity and are they making money or loss-making?

Company's Response:

Due to the Circuit Breaker measures introduced by the Singapore Government, the pre-school has not been operational. However, the pre-school remained profitable as there were additional funding support from the government.

Children have returned to the preschool since 2 June 2020 and the preschool is now operating in a similar capacity before the Circuit Breaker measures were implemented.

Question 6:

Share Price: The majority shareholders bought a substantial stake in the Company for 3.0595 cents and Placement shareholders bought in the Company at 2.7 cents. Despite repeated attempts and positive news, the Company's share price have been battered down and under valued. What steps are the Management doing to help support the share price and allow investors to better appreciate the Company's true value?

Company's Response:

The Board and management team will continue to do our best to deliver value to the Company.

At OEL, the Company will continue to develop its businesses and dealing with all parties based on our Company's culture statement which is "Fairness, Transparency, Professional, and Integrity".

Question 7:

With respects to the Share Issue Mandate, can the Company elaborate more on its purpose especially given the dilutive effects such share issues may cause for existing shareholders. Already the recent placement gives free warrants to the places and at lower prices that the recent 3.0595 cents price that the Substantial Shareholder bought at, what assurances can the Management give that they will NOT keep issuing shares at lower prices?

Company's Response:

The resolution on Share Issue Mandate is tabled to shareholders to allow the Company to have the flexibility to issue further shares, if required. The Board is fully aware of the dilutive nature of issuance of new shares and warrants. If there is any new issue of shares, it will be issued in the best interest of the Company.

The Company wishes to emphasise that it will remain responsible to its shareholders and society, maximizing the interests of shareholders while creating social value.

Most importantly, we wish to be sustainable in what we do and include sustainable practices to create long-term value for our shareholders and all stakeholders.

By Order of the Board

Zhao Xin
Chief Executive Officer and Executive Director
25 June 2020

This announcement has been reviewed by the Company's sponsor, RHT Capital Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The details of the contact person for the Sponsor are:

Name : Mr Shervyn Essex (Registered Professional, RHT Capital Pte. Ltd.)
Address : 9 Raffles Place, #29-01 Republic Plaza Tower 1, Singapore 048619
Tel : 6381 6966
